JP6357470B2 - 改良されたｃｄ３１ペプチド - Google Patents

改良されたｃｄ３１ペプチド Download PDF

Info

Publication number
JP6357470B2
JP6357470B2 JP2015517753A JP2015517753A JP6357470B2 JP 6357470 B2 JP6357470 B2 JP 6357470B2 JP 2015517753 A JP2015517753 A JP 2015517753A JP 2015517753 A JP2015517753 A JP 2015517753A JP 6357470 B2 JP6357470 B2 JP 6357470B2
Authority
JP
Japan
Prior art keywords
peptide
seq
disease
amino acid
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015517753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521611A (ja
JP2015521611A5 (enExample
Inventor
カリジウリ，ジュゼッピーナ
ニコレッティ，アントニーノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Universite Paris Diderot Paris 7
Universite Sorbonne Paris Nord
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Universite Paris Diderot Paris 7
Universite Sorbonne Paris Nord
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Universite Paris Diderot Paris 7, Universite Sorbonne Paris Nord filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of JP2015521611A publication Critical patent/JP2015521611A/ja
Publication of JP2015521611A5 publication Critical patent/JP2015521611A5/ja
Application granted granted Critical
Publication of JP6357470B2 publication Critical patent/JP6357470B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
JP2015517753A 2012-06-19 2013-06-19 改良されたｃｄ３１ペプチド Active JP6357470B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305697 2012-06-19
EP12305697.0 2012-06-19
PCT/EP2013/062806 WO2013190014A1 (en) 2012-06-19 2013-06-19 Improved cd31 peptides

Publications (3)

Publication Number Publication Date
JP2015521611A JP2015521611A (ja) 2015-07-30
JP2015521611A5 JP2015521611A5 (enExample) 2016-07-07
JP6357470B2 true JP6357470B2 (ja) 2018-07-11

Family

ID=48652100

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517753A Active JP6357470B2 (ja) 2012-06-19 2013-06-19 改良されたｃｄ３１ペプチド

Country Status (11)

Country Link
US (1) US10815272B2 (enExample)
EP (1) EP2861241B1 (enExample)
JP (1) JP6357470B2 (enExample)
DK (1) DK2861241T3 (enExample)
ES (1) ES2877513T3 (enExample)
HR (1) HRP20211017T1 (enExample)
HU (1) HUE055593T2 (enExample)
PL (1) PL2861241T3 (enExample)
PT (1) PT2861241T (enExample)
SI (1) SI2861241T1 (enExample)
WO (1) WO2013190014A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069586A (zh) * 2016-03-21 2018-12-21 国家健康与医学研究院 用于再灌注损伤的预防和/或治疗的cd31shed激动剂
JP7166512B2 (ja) * 2016-05-03 2022-11-08 インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル （インセルム） 炎症のイメージングのための分子標識としてのＣＤ３１ｓｈｅｄ
US20220001083A1 (en) * 2018-11-27 2022-01-06 Balt Extrusion Method for the modification of a device surface by grafting a cd31-derived peptide onto the surface of said device
WO2020109833A1 (en) 2018-11-27 2020-06-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for the modification of a substrate surface by grafting a peptide onto the surface of said substrate
WO2023099932A1 (en) * 2021-12-03 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd31 mimetic coating for endovascular stent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087331A (en) 1990-01-19 2000-07-11 The Blood Center Of Southeastern Wisconsin Therapeutic use of platelet-endothelial cell adhesion molecule-1 compositions
JP3914988B2 (ja) * 2003-08-06 2007-05-16 国立大学法人名古屋大学 細胞死誘導のためのペプチドおよび医薬
EP2313432B1 (en) * 2008-06-30 2017-09-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders
WO2013152919A1 (en) 2012-04-11 2013-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Detection of platelet-derived shed cd31

Also Published As

Publication number Publication date
HRP20211017T1 (hr) 2021-10-01
SI2861241T1 (sl) 2021-11-30
JP2015521611A (ja) 2015-07-30
EP2861241A1 (en) 2015-04-22
PL2861241T3 (pl) 2021-10-25
US20150203536A1 (en) 2015-07-23
EP2861241B1 (en) 2021-04-28
ES2877513T3 (es) 2021-11-17
DK2861241T3 (da) 2021-07-05
HUE055593T2 (hu) 2021-12-28
PT2861241T (pt) 2021-07-02
US10815272B2 (en) 2020-10-27
WO2013190014A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
US10253085B2 (en) CD31 peptides for the treatment of thrombotic or autoimmune disorders
Kubota et al. Involvement of dipeptidyl peptidase IV in an in vivo immune response
JP2019104754A (ja) アネキシン−１（リポコルチン１）をモジュレートすることによる自己免疫疾患の処置方法
JP6357470B2 (ja) 改良されたｃｄ３１ペプチド
CN102282169A (zh) 表达破骨细胞相关受体的细胞活性和分化的调节
AU2021202634B2 (en) Hla-b57 open conformers
JPH10504039A (ja) 多発性硬化症のための組成物および治療法
JP2017523963A (ja) 移植拒絶の予防及び自己免疫疾患の治療に使用するための単離されたインターロイキン−３４ポリペプチド
US20210380683A1 (en) Modulation of irf-4 and uses thereof
EP2989121B1 (en) Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
AU2019386379B2 (en) DPEP-1 binding agents and methods of use
JP2019512520A (ja) 再灌流傷害の予防および／または治療に使用するためのＣＤ３１ｓｈｅｄアゴニスト
EP3356389A1 (en) Use of human derived immunosuppressive proteins and peptides as medicaments
Jucaud et al. Immunobiology of HLA class-Ib molecules in transplantation
JP2012530106A (ja) ＨＬＡ−Ｇα１多量体及びその薬学的使用
US20160158330A1 (en) Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
Roelofs et al. Expression of Toll-like receptor (TLR) 2, TLR3, TLR4 and TLR7 is increased in rheumatoid arthritis synovium and regulates cytokine production by dendritic cells upon stimulation of TLR specific pathways
King et al. Amelioration of joint inflammation by a PAR-2-specific monoclonal antibody
Kelso et al. Tryptase as a PAR-2 activator in joint inflammation
Karper Damage associated molecular patterns and toll like receptors in inflammation
Wesoly et al. PTPN22 as a rheumatoid arthritis susceptibility but not severity gene
Bessis et al. Active immunization (vaccination) against peptides of IL-1β induces self anti-IL-1β antibodies and protects against collagen-induced arthritis
Miranda et al. Methotrexate, through adenosine release, downregulates tumor necrosis factor alpha-induced synovial fibroblast IL-15 expression and proliferation
Sattler T-cell receptor-independent induction of interferon gamma expression in human memory Th cells

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180522

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180618

R150 Certificate of patent or registration of utility model

Ref document number: 6357470

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250